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Abstract
Type 2 diabetes mellitus (T2D) is a multifactorial and genetically heterogeneous disease which leads to impaired glucose
homeostasis and insulin resistance. The advanced form of disease causes acute cardiovascular, renal, neurological and
microvascular complications. Thus there is a constant need to discover new and efficient treatment against the disease by
seeking to uncover various novel alternate signalling mechanisms that can lead to diabetes and its associated
complications. The present study allows detection of molecular targets by unravelling their role in altered biological
pathways during diabetes and its associated risk factors and complications. We have used an integrated functional networks
concept by merging co-expression network and interaction network to detect the transcriptionally altered pathways and
regulations involved in the disease. Our analysis reports four novel significant networks which could lead to the
development of diabetes and other associated dysfunctions. (a) The first network illustrates the up regulation of TGFBRII
facilitating oxidative stress and causing the expression of early transcription genes via MAPK pathway leading to
cardiovascular and kidney related complications. (b) The second network demonstrates novel interactions between GAPDH
and inflammatory and proliferation candidate genes i.e., SUMO4 and EGFR indicating a new link between obesity and
diabetes. (c) The third network portrays unique interactions PTPN1 with EGFR and CAV1 which could lead to an impaired
vascular function in diabetic nephropathy condition. (d) Lastly, from our fourth network we have inferred that the
interaction of b-catenin with CDH5 and TGFBR1 through Smad molecules could contribute to endothelial dysfunction. A
probability of emergence of kidney complication might be suggested in T2D condition. An experimental investigation on
this aspect may further provide more decisive observation in drug target identification and better understanding of the
pathophysiology of T2D and its complications.
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Introduction
Diabetes is a serious health problem in society, and about 90%
of the diabetic population is affected with T2D [1]. According to
the International Diabetes Federation (IDF) approximately 246
million adults in the seven IDF countries were living with T2D in
2007. This number is expected to increase to 380 million by 2025
(IDF, http://www.idf.org/). The disease is characterized by
impaired glucose homeostasis, decreased insulin activity and
insulin resistance which lead to elevated blood glucose levels
[2,3]. The advanced form of the disease causes acute cardiovas-
cular, renal, neurological and organ complications [4–8].
This metabolic condition is determined by the interaction of
various environmental and genetic factors. Obesity is a major risk
factor in T2D development [9]. Elevated levels of free fatty acids
(FFA) in obesity promote interactions between FFA, lipid
metabolites, inflammatory pathways and mitochondrial dysfunc-
tion [10–12]. Research investigations to unravel the molecular
mechanism of T2D have led to the identification of multiple
signalling and metabolic pathways that get altered during the
disease. Insulin resistance is the main underlying cause of several
transcriptionally altered signalling and metabolic pathways in T2D
which later lead to defective microvascular, macrovascular and
endothelial functions [13]. Thus far, alteration in signalling
pathways mediated by insulin, adipocytokines, FFA, EGF, Jak/
STAT, MAPK, VEGF, PPAR, PI3-K and Wnt have been reported in
the pathogenesis of T2D. EGF exerts insulin like effects on glucose
transport and lipolysis and can increase the tyrosine phosphory-
lation and activation of IRS-1 and IRS-2. EGF is also capable of
activating additional PI3-K pools and, thereby augments the
downstream signalling of insulin in insulin-resistant states like T2D
[14]. It has been found that high glucose concentration causes
production of TGFB and activates Jak/STAT signalling cascade in
diabetic kidney cells. Activation of this signalling cascade can
stimulate excessive proliferation and growth of glomerular
mesangial cells, contributing to diabetic nephropathy [15,16].
Exposure to high glucose concentration has also been shown to
activate MAPK signalling pathway in skeletal muscle cells [17].
Impairment in VEGF signalling has been noticed in T2D.
Chronic coronary heart disease in diabetic patients is character-
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expression of its receptors along with down-regulation of its signal
transduction resulting in reduced neoangiogenesis [18]. Signalling
pathway mediated by PPAR is down-regulated in diabetes [19].
Mitogenic stimulation mediated by MAPK signalling cascade
suppresses PPARG activity [20]. PI3-K is a key molecule in insulin
signalling which is found to be down-regulated in T2D [21]. Wnt
signalling process plays an important role in pancreatic beta-cell
development by promoting expression of Pitx2 and CyclinD2
which regulate beta cell cycle progression [22]. Reactive oxygen
species (ROS) production by FFA has also been implicated in
pancreatic cell death. ROS activates NF-kB which eventually leads
to apoptosis and/or necrosis of beta cells [23]. Thus it is seen that
attenuation in insulin signalling seems to affect/induce cross-talk
among various processes responsible for apoptosis, endothelial
dysfunction and vascular dysfunction [24,25]. Other than these
pathways, a number of genes have been discovered to be
candidates to cause T2D.
The aim of this study is to put forth novel biological networks
that describe transcriptional alteration (up and/or down-regula-
tion) in genes/pathways which could contribute to the pathogen-
esis of T2D and its associated complications. Knowledge and
statistics based systematic analysis of high throughput molecular
data from normal and diseased individuals can be used to
construct candidate molecular networks. An extensive analysis of
these networks facilitates the identification of pathways and genes
affected during the disease process. Similar approach is compre-
hensively being used to identify candidate genes and biomarkers
for various complex diseases including cancers and diabetes [26–
29]. Bergholdt et al [30], identified loci showing genetic
interactions associated with Type 1 Diabetes (T1D) using genome
scan data. By elucidating possible epistasis between classic T1D
loci, major T1D predictive signals (marginal markers) were
characterized and fine mapped. In order to elucidate/identify
underlying biological interactions and novel candidate genes, the
genetic epistasis analysis data were integrated with protein
networks spanning the interacting epistatic regions and scanned
for functional sub networks.
We have applied a network biology approach which involves
the integration of co-expressed gene network with corresponding
protein interaction network to identify signature networks. In our
study, we have worked with microarray data comprising diabetic
and other complications. Instead of selecting genes from
susceptible diabetic risk loci, we have considered all those genes
that appeared differentially expressed in our analysis. The genetic
networks were integrated with corresponding protein interaction
networks. Integration of independent but biologically related
genetic, molecular and regulatory information appears as a
reliable method to obtain insights into functional modules which
allow detection of previously unknown deregulated pathways [31–
33]. Through this approach we tried to assess the interactions of
known T2D candidate genes with other molecules in different
biological pathways and a few unique interactions which could
result in new, non-obvious hypotheses that are statistically
significant.
In the work we present here, microarray gene expression data
analysis identifies transcriptionally altered key genes involved in
signalling/metabolic pathways of T2D. In addition, the protein-
protein interaction data enables understanding of the protein
complexes and their molecular organization in the overall
topology of the networks. The combined analysis of expression
profiles and protein-protein interaction data in integrated
networks have been shown to generate significant molecular
mechanisms and pathways. Our results depict their potential
involvement in diabetes progression and various associated
complications as well.
In the current study we have computationally constructed four
new sub networks and on analyzing these networks, we have
proposed different possible alterations of signalling pathways in
these networks. We have predicted novel molecular regulators
(unique genes and interactions) which could have an impact on the
pathophysiology of T2D and its complications via various
significant pathways such as insulin signalling, oxidative metabo-
lism, Wnt signalling and others. The present system level network
biology analysis from diabetes and obesity microarray expression
datasets shows that the interaction across TGFBRII, SMAD3 and
GCR along with FFA can induce vascular complications in
diabetes. It is suggested from the study that GAPDH, a significant
enzyme in carbohydrate metabolism, can induce micro vascular
complications and faulty insulin signalling in association with
SUMO4, growth factor EGFR and IRS in diabetic and obese
individuals. A careful modular dissection and examination of
networks from diabetic nephropathy datasets exhibit the interac-
tions between EGFR with PTPN1 and CAV1 through AKT1
activation. Analyses of the three large transcriptionally altered
diabetic datasets (Mexican_Hs, IR_Hs and DN_Hs) demonstrate
that the oxidative stress induced deregulation of b-catenin plays an
important role in causing kidney diabetic complications by the
down-regulation of CDH5.
Materials and Methods
Details of Microarray Datasets
Seven studies from human and one study from mouse
encompassing a set of 138 microarray expressions from human
and 12 from mouse have been selectively retrieved from GEO
(Gene Expression Omnibus) datasets and Diabetes Genome
Anatomy Project for the present analysis. The selection of
microarray expression studies is based on the following criteria:
(i) studies that examine the insulin resistance associated with T2D
pathogenesis (ii) nephropathy as one of the major T2D associated
complications (iii) obesity contributing to insulin resistance via the
development of cardiovascular disease and (iv) inflammation
caused by obesity. All the datasets have been named according to
the study type as prefix and species as suffix (Studytype_Species),
‘Hs’ indicating human dataset and ‘Mm’ indicating mouse
dataset. All the datasets along with their tissue source and
number of control and diseased samples have been detailed in
Dataset S1. Aiming to address different altered biological
pathways and gene/protein interactions in T2D, we focused on
those datasets which could be more related to the problems
associated with this disease.
Dataset IR_Hs originally reports that the differentially
expressed genes in insulin resistance of skeletal muscle cells are
susceptible genes for T2D [34]. The datasets Preadipocyte_Hs and
Adipocyte_Hs describes obesity induced inflammatory response in
preadipocytes and adipocytes cells [35,36]. Another dataset,
Obs_Hs, reports differentially expressed obesity responsive genes,
which further relates to T2D pathophysiology through insulin
resistance [37]. Expression analysis from PCOS_Hs dataset shows
that the obesity can cause polycystic ovary syndrome, which is
independent of insulin resistance in women [38]. Kidneys are
highly affected in acute diabetic condition. DN_Hs and Renalfai-
lure_Mm describe diabetic nephropathy in the kidney tissue and
loss of its damage repair capability [39,40]. Mexican_Hs dataset
reports differentially expressed genes specific to insulin resistance
and T2D [41].
Network Biology
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Each dataset is normalized in order to bring the unit variance
across the data using the following two steps: (a) Calculation of
row-wise mean and standard deviation for each gene in all the
data files. (b) Subtraction of mean from each expression value
(from both control and diseased sets) followed by the division of the
resultant value by standard deviation. This is done across all the
datasets. Figure 1 illustrates the overall method.
Selection of Genes
Each dataset varies in terms of experimental conditions, types
and numbers of samples and the number of differentially expressed
genes. Therefore, identification of the significant genes from each
dataset is a crucial step in the process of analysis. DNA Chip
Analyzer [42] has been used for comparing the microarray
datasets (diseased vs. controls). Differentially expressed genes are
identified from the normalized datasets at the cut-off p-value
,=0.05 and fold change value .=1.5 and ,=21.5. Genes
satisfying these conditions are grouped separately as up-regulated
and down-regulated genes (Dataset S2).
Construction of Protein-Protein Interaction Network
Protein-protein interaction network for each set of up and
down-regulated genes has been constructed by APID2NET, an
implemented plug-in of Cytoscape [43]. APID2NET retrieves all
the possible information on protein-protein interaction from five
interaction databases namely, Database of Interacting Proteins
[44], Biomolecular Interaction Network Database [45], IntAct
[46], Molecular Interactions Database [47] and Human Protein
Reference Database [48]. Swissprot/Uniprot IDs for each group
of genes have been collected from APID database [49] and then
imported to Cytoscape via its plug-in. The up-regulated and
down-regulated genes from each study were separately submitted
in APID2NET and the networks were analyzed in Cytoscape
platform.
Construction of Co-Expression Network
The expression similarity across the gene datasets was derived
using Pearson’s correlation coefficient (r-value). A Pearson’s
correlation coefficient gives the measurement of the degree of
the correlation between two variables. Cladist software was used to
Figure 1. Overview of integrated network of gene-gene co-expression and protein-protein interaction information of microarray
data (1-6). (1) All the datasets have been filtered through the defined cut-off of student’s t-test and fold change value. The differentially expressed
up and down-regulated genes were sorted to make separate lists. (2) The co-expression network was constructed by calculating Pearson’s correlation
coefficient (r-value) for each gene pair. And the top-ranking genes (r-value varies for the datasets) were used to construct the co-expression network.
The corresponding gene sets were processed to generate the protein-protein interaction networks. (3) & (4) Both the networks were merged to get
the final large network. The statistical validation of the large network was done using Wilcoxon test. (5) The potential sub-networks were identified
using an in-house Java program. (6) Sub-networks were further validated through Wilcoxon test. The other validation parameters like average
clustering coefficient, average degree and network density have also been calculated to assess the statistical significance of the network.
doi:10.1371/journal.pone.0008100.g001
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[50]. An in house java program was written to rank the gene-pairs
on the basis of their correlation values. It generates a symmetrical
n x n matrix at a given r cut-off value (range: 0.6–0.9). The rank
matrix was imported in Cytoscape to construct the network of co-
expressed genes.
Construction of Integrated Gene Networks Using
Expression and Interaction Data
In network organization each gene or protein is represented as a
node. The number of interactions or links that a node has with
other nodes is defined as a degree. Co-expression network
comprises nodes which correspond to genes and the edges
corresponding to co-expression links. The protein-protein inter-
action network obtained from APID includes information on co-
interacting proteins, defined as proteins that have physical
interaction. APID provides known experimentally validated
protein-protein interactions. The edges in the integrated functional
network correspond to both co-expression and physical protein-
protein interactions.
The approach underlying the present study utilizes an
integrated concept of merging the gene-gene co-expression
correlation matrix and protein-protein interaction data to
construct the complete networks (eight studies). Integration refers
to the process of combining networks by merging nodes that share
a particular GO annotation, or nodes whose gene expression
levels change significantly in one or more conditions according to
p-values loaded with the gene expression data. Integrated
networks were created by overlapping nodes that were common
to both co-expression and protein interaction networks. Both co-
expression networks and protein interaction networks were
integrated using Cytoscape plug-in which identifies the genes by
their ID types. These networks have many embedded sub-
networks with significant biological functions relevant to T2D
pathogenesis.
Searching of High-Scoring Sub-Networks
A sub-network of large protein-protein interaction network can
be defined as the set of statistically and functionally significant
interacting genes. The potential sub-networks have been identified
by a search method estimating their significance scores [30]. The
significance score (S) is calculated as, S=average (s1,s 2,…, sn),
where ‘s’ is the individual node score. ‘s’ for each node is computed
by dividing the total number of direct interactions (i.e., first order
neighbors) of that node by the average degree present in the sub-
network. A cut-off value of 0.5 is set to consider those nodes which
have significant number of interactions in the network. Nodes with
higher than 0.5‘s’ value have been taken for further search. All the
individual node scores have been averaged to get the final ‘S’
score. The threshold value for ‘S’ score has been set as 1 and sub-
network showing higher than this value has been taken into
consideration. The four sub-networks showing high scores have
analyzed in the succeeding sections. Thus the sub networks were
extracted from the larger networks generated by integrating
expression data and interaction data. They were further assessed
statistically and analyzed using the information available from
literature sources and online repositories to verify their biological
functions pertaining to T2D.
Evaluation of Topological and Statistical Measures of the
Sub-Networks
The topological and statistical significance of each sub-network,
abstracted from large networks have been calculated using
Cytoscape plugins Network Analyzer [51] and CentiScaPe [52].
We have used the following network biology concepts to evaluate
the topology and extent of clustering in the candidate sub-
networks:
Topological coefficient for node n1 is computed as TC
(n1)=average (J(n1,n 2)/kn1), where J(n1,n 2) gives the value of
the number of nodes shared by both n1 and n2 nodes and kn1 is the
number of interactions of node n1.
Average clustering coefficient measures the average of
clustering coefficients of all nodes, which are defined as the
ratio of the number of edges between the neighbours of a node
to the maximum number of edges that could possibly exist
b e t w e e nt h e m .I tc a nb ee x p r e s s e da sC( n ) = 2 e n/(kn(kn-1)),
where kn is the no. of interactions of node n and en is the no. of
connected pairs between all neighbours of node n. Log-log
graphs have been constructed by plotting the number of
neighbours ‘‘k’’ on x-axis and the average clustering coefficient
‘‘C(k)’’ and topological coefficient ‘‘TC(k)’’ as the functions of k
on y-axis.
Average degree measures the average of all connectivities of a
node. This is extended by network density, which indicates the
compactness of one network distributed through its edges. The
results were further refined for all the sub-networks by estimating
Wilcoxon test in R package.
Usually centrality measures are used to capture the structure of
node in the network and identify the hub proteins. The simplest
measure of all centralities is node degree distribution. The degree
of a node v is the number of nodes that are directly connected to it
i.e. first neighbours of node v. We calculated the degree
distribution P (k), which determines the probability of node v
with k number of links, where k=1, 2…This pattern of structure
obeys the power law P(k) , k
2c, where c is a constant called
degree exponent indicating the scale-freeness of networks. By
fitting a line to the given sets of data the pattern of their
dependencies can be seen which can be used to validate the scale-
free topology of the networks. The software used here uses least
square method [53] and considers only the data points with
positive co-ordinate values for fitting the line, where the power-law
curve is y=b x
a. This model is transformed into ln y=lnb+a ln x.
When a plot is made and the coefficient of determination, R
2 of
the regression line is computed, the network models can be tested
based on this value [54]. The R-squared value measures how well
the data points fit to the curve.
Another centrality measure, the betweenness centrality calcu-
lates a value of a node (n1) that is located in the shortest path of
two other nodes (n2 and n3) and indicates its significance in the
communication of these two nodes [55]. The betweenness value of
n1 can be expressed as,





r n2 ,n1 ,n3 ðÞ =r n2 ,n3 ðÞ , n1 =n2 =n3
Here r (n2,n 3) is the number of shortest paths starting at node
n2 and ending at node n3. The value of r (n2,n 1,n 3) indicates the
number of those shortest paths which pass through node n1 in the
network.
Scale-Freeness Topology of the Networks
Biological networks have been characterized by topological
features which establish their scale-freeness property [56]. Protein
interaction networks and co-expression networks also exhibit a
scale-free geometry, where the nodes are not uniformly populated
with neighbours. All the nodes of these networks do not follow the
Network Biology
PLoS ONE | www.plosone.org 4 December 2009 | Volume 4 | Issue 12 | e8100rule of having an average number of links per node. Most of the
nodes have few partners, while a few nodes also called ‘hubs’
interact with many partners [26]. Power law process is used for
estimating the parameters and validating the network models with
their scale-freeness property. Usually R-squared values closer to 1
indicate higher correlation and a stronger linear relationship
between the data variables. Here also the R-squared values obey
the rule emphasising that the networks are scale-free i.e., they are
unevenly populated with hubs and less dense nodes. Biological
networks are found to be very sensitive to the removal of hub
proteins. It has been observed that the deletion of hub proteins in
yeast protein-protein interaction network exerts an increased
lethal effect [57]. In the present study is has been observed that
the hub proteins are communicating with many other significant
proteins involved in many pathways reported to be affected
during T2D. Further biochemical investigation on the removal of
these hub proteins needs to be conducted to provide better
understanding in the roles played by them in the pathophysiology
of T2D.
Analysis of Functional Enrichment of the Networks
In order to identify how the networks are functionally
embellished we used GOlorize, a Cytoscape plug-in [58]. It is
based on a hyper geometric test with Benjamini and Hochberg
false discovery rate (FDR) corrected p-value and displays the
overrepresented functional gene ontology (GO) categories in a
given network. The major functional categories have been taken to
construct pie diagrams based on their overall frequencies in a
network.
Validation of Novel Interactions
Two new interactions observed in the networks were validated
by the identification of their interacting domains. InterDom
[59,60] was used to predict the interacting domains for each
protein pair and further verified using 3did [61].
Results
Larger integrated networks are constructed by the union of
gene-gene expression correlation information and protein-protein
interaction data. Microarray data analysis from studies like
obesity, insulin resistance, T2D and kidney failure in diabetes
contribute to infer some significant physiological pathways and
biological processes related with T2D pathophysiology and
complications. The statistical significance analysis of networks
has led to the identification of four signature sub-networks that
show the interaction across several important metabolic/signalling
processes, transcription factors and pathways in T2D. These sub-
networks have been further investigated to learn the functional
relevance pertaining to disease mechanism which is discussed as
follows (Table 1).
GCR Over-Expression Leads to FFA Production, which in
Turn Induces c-Fos/c-Jun Activity through the
Interactions of TGFBRII
A signature network (named as TranscriptionFactors_Kidney-
Complication) obtained from three different datasets viz.,
Mexican_Hs, Obs_Hs and PCOS_Hs delineates functional
relationship between proto-oncogenes, transcription factors,
MAPK pathway and FFA. The network topology is made of 52
nodes and 146 interactions (p value 1.08610
25). From the given
network we identified c-Fos and MAPK1 as hub genes, while c-Jun
and GCR interacted directly with the hubs (Figure 2). TGFBRII is
shown to link the two hub genes. This network module suggests a
relation between FFA, interacting partners of proto-oncogenes like
c-Fos and c-Jun, transcription factor GCR, ATP dependent
chromatin remodeling factor SMAD3 and their interaction with
TGFB and MAPK pathways.
GCR has been reported to be over-expressed in obesity and
cause insulin resistance [62], and is observed in the signature
network. Potent up regulation of GCR may be considered to
represent increased glucocorticoids activity and as inferred from
literature, elevated GC action is observed in obesity, insulin
resistance, T2D and cardiovascular complications. Effect of GC
includes impaired insulin-dependent glucose uptake in the
periphery and enhanced gluconeogenesis in the liver leading to
insulin resistance. GC and TGFB aid in the production of FFA and
oxidative stress [63,64]. This network module shows TGFB-
TGFBRII interaction causing activation of transcription of several
TGFB inducible genes via Smad signalling pathway. SMAD3 is an
interacting partner for TGFBRII and is up-regulated in the
network. Increase in expression of TGFBR, c-Fos and c-Jun is also
observed clustered in co-expression gene network. TGFBR
signalling occurs mainly through the activation of Smad pathway
[65]; however it may also involve MAPK/ERK1/2 pathways in
certain cell types, such as endometrial epithelial cells and
endometrial stromal cells under certain conditions [66].
Thus the sub network displays activation of growth related
proto-oncogenes such as, c-Fos and c-Jun mediated by TGFB and
also involving GCR.
Over-Expression of SUMO4 and GAPDH in Response to
Oxidative Stress Induces EGFR Signalling to Increase
Vascular Complications and Impair Insulin Signalling
Signature network from Obs_Hs and IR_Hs consists of 48
nodes and 162 interactions (p value 1.92610
27). This network
module has been named as GAPDH-EGFR_MicrovascularCom-
plication. It has GAPDH and EGFR as hub genes. SUMO4, IRS-1
and 14-3-3 zeta interact directly with these hub genes. It can be
seen that 14-3-3 zeta links the two hubs (Figure 3).
SUMO4, GAPDH and EGFR are significantly over expressed in
this study and are noted to interact with each other in the network.
Table 1. Four top-scored significant networks displaying their corresponding total number of nodes, edges and p-values.
Significant networks Number of nodes Number of edges p-values (Wilcoxon test)
TranscriptionFactors_KidneyComplication 52 146 1.08610
25
GAPDH-EGFR_MicrovascularComplication 48 162 1.92610
27
Akt/Pi3k pathway_VascularDysfunction 98 357 2.20610
210
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appear here from the datasets of T2D and its associated
complications. Based on these observations we predicted novel
interactions between SUMO4 and GAPDH, and GAPDH and EGFR.
These interactions were further validated using domain and motif
information to strengthen the predictions as explained in the
subsequent segments.
The interaction between the glycolytic protein GAPDH and
inflammatory SUMO4 suggests a potential role in the development
of insulin resistance. EGFR, an important growth factor receptor,
is noted to be up-regulated in diabetic kidney [67,68]. EGF
suppresses proteolysis via PI3-K in renal tubular cells and increases
abundance of GAPDH [69]. The interaction of GAPDH with EGFR
as visualized in our network implicates a probable role in insulin
signalling. EGFR interacts with 14-3-3 zeta and results in its up
regulation as shown in the network. The interaction is mediated
through EGF to advance EGFR signalling [70]. 14-3-3 zeta
interacts with IRS-1 in this network. In the given network we
also observe the up regulation of serine/threonine kinase which
participates in EGF signalling.
AKT-1/PI3-K Pathway Is Up-Regulated through Increased
Expression of EGFR Eventually Exhibiting Its Two Unique
Interactions with PTPN1 and CAV1 in Diabetic
Nephropathy
Sub-network, Akt/Pi3k pathway_VascularDysfunction obtained
from diabetes associated with nephropathy datasets namely,
DN_Hs and Renalfailure_Mm consists of 98 nodes and 357
interactions (p value 2.20610
210). AKT1 and IRS-1 are identified as
hub genes which interact with each other directly. Figure 4 displays
the causal relationships of EGFR with AKT1/PI3-K pathway in
diabetic nephropathy. It also suggests two new interactions between
EGFR, PTPN1 and CAV1 reported for the first time in kidney
complications associated with T2D in the network.
Figure 2. TranscriptionFactors_KidneyComplication network illustrates the interaction of proto-oncogenes with SMAD molecules
and nuclear receptors (A-B). All the nodes and edges are in green and purple color respectively. The key molecules which are significantly
expressed through their interactions with other molecules in the network are highlighted as orange. The hub molecules are also colored as purple. A.
Interaction overview (constructed and analyzed in Cytoscape): a skeletal structure of the main sub-network showing only the significant molecules in
orange, their biological roles and pathological conditions in blue. B. Expanded view of the network imported from Cytoscape: Network explains the
interaction of TGFBRII and SMAD3 being modulated by the increased expression of GCR (and FFA). This interaction in turn induces expression of early
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cells exhibiting its characteristic feature of matrix protein
accumulation [71]. High glucose condition is found to induce
the PI3-K/AKT pathway in kidney messengial cells of rodent
models mediating insulin signalling through the phosphorylation
of IRS-1. This subsequently results in over production of collagen I
in these cells. Further, the up-regulation of EGFR has also been
reported as a requirement for AKT activation [72]. An interaction
between EGFR and PTPN1 has been observed in this network.
The occurrence of PTPN1 is reported in T2D [73]. Protein coded
by this gene acts as a key phosphatase for EGFR. The phosphatase
activity of PTPN1 is observed to regulate the recruitment of
different signals to EGFR, which is considered as an important hub
molecule in many signalling pathways [74]. Another significant
interaction that has been observed here is the interaction between
PTPN1 and CAV1. It has been identified as a candidate gene for
T2D [75].
On the basis of these observations supported by the literature,
we have proposed the interactions of PTPN1 with EGFR and with
CAV1 as the new potential interactions in diabetic nephropathy.
Since individually all three molecules are reported to be associated
with T2D, it can be suggested that their interactions also might
play some significant roles in this disease development.
Increased Mitochondrial ROS Production Up-Regulates
VE-Cadherin Mediated by Wnt Signalling Leading to
Vascular Complications
An important signature sub-network noted in three datasets
namely, IR_Hs, DN_Hs and Mexican_Hs, shows interaction of
pathways causing the generation of ROS, Wnt and TGF-beta
pathways. b-catenin has been identified as an important hub
which interacts with significant genes such as GSK-3B, CDH5,
SMAD and TGFBRI. The network, named as Wnt_VascularCom-
Figure 3. GAPDH-EGFR_MicrovascularComplication network shows EGFR induced insulin resistance and impaired GAPDH induced
micro vascular complications (A-B). All the nodes and edges are in green and purple color respectively. The key molecules which are significantly
expressed through their interactions with other molecules in the network are highlighted as orange. Themolecules connecting two portions of the sub-
network are colored as grey. The hub molecules are also colored as purple. A. Interaction overview (constructed and analyzed in Cytoscape): a skeletal
structure of the main sub-network showing only the significant molecules in orange, their biological roles and pathological conditions in blue. B.
Expanded view of the network imported from Cytoscape: It shows interaction between stress responsive expression of GAPDH with insulin, SUMO4 and
EGFR. The GAPDH and EGFR hubs are interacting directly and are also connected through Androgen receptor, MAPKKK14 and 14-3-3 protein zeta/delta.
Interaction of GAPDH and EGFR and subsequent interaction with 14-3-3 zeta imply their significance in developing insulin insensitivity.
doi:10.1371/journal.pone.0008100.g003
Network Biology
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in these pathways, which further correlates with the significant
clinical observations in diabetes subjects. It contains 49 nodes and
153 interactions (p value 7.39610
27).
It has been observed that DNM1L and FIS1 genes are involved
in the maintenance of mitochondrial morphology [76,77].
Illustratively, the proteins produced by FIS1 and DNM1L are
noted to be over-expressed and Wnt expression is down-regulated
in the networks from expression datasets (Figure 5). DNM1L
interacts with the molecules of Wnt signalling like GSK-3B, thereby
regulating its down-stream signalling [78]. Higher expression of
GSK-3B is thought to cause proteosomal degradation of b-catenin
via the formation of a cytoplasmic multiprotein complex [79,80].
Furthermore, the literature exploration on b-catenin reveals that it
gets down-regulated in diabetes nephropathy [81]. In this network
b-catenin has been observed to be associated with CDH5. It is well
established that T2D is often associated with cardiovascular
complications where endothelial dysfunction acts as a hallmark. It
has been shown that the up-regulation of CDH5 acts as an
indicator of coronary artery disease in patients with diabetes
mellitus [82]. Therefore, it is the first instance, where CDH5 and
Wnt are predicted to interact and subsequently lead to vascular
complications in diabetes (Figure 5B). Another hub in the network,
TGFBR I has been recognized as one of the major contributors to
diabetic nephropathy mediated by the TGFB-signalling pathway
[83]. b-catenin has been found to become associated with TGFB-
signalling via its interaction with Smad molecules [84]. These
interactions have been noted from the datasets of T2D and
diabetic nephropathy as mentioned above. On the basis of these
observations we have proposed that these causal relationships
might play significant roles in developing kidney complications in
diabetes mellitus.
Figure 4. Akt/Pi3k pathway_VascularDysfunction network shows up-regulation of this pathway through increased expression of
EGFR leading to diabetic nephropathy and exhibits two unique interactions of EGFR with PTPN1 and CAV1 (A-B). All the nodes and
edges are colored as green and purple respectively. The key molecules which are significantly expressed through their interactions with other
molecules in the network are highlighted as orange. The hub nodes which have been described here are in purple color. A. Interaction Overview
(constructed and analyzed in Cytoscape): a skeletal structure of the main sub-network showing only the significant molecules in orange and
pathological conditions caused by them in blue. B. Expanded view of the network imported from Cytoscape: Different pathways interaction from
diabetic nephropathy datasets have been shown here. Deregulated inflammatory cytokines, AKT1 and eNOS involved in kidney dysfunction are
shown in this sub-network. Yellow-coloured genes are very significant in this disease pathology.
doi:10.1371/journal.pone.0008100.g004
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Parameters
Considering the selection criteria of data sets and to identify the
altered pathways and gene/protein interactions, we paired our
datasets to analyze further. After an exhaustive search of large
integrated networks constructed from the selected data sets we
identified small putative sub networks. Network topology is
thought to render the significance of a node in communicating
with other genes or proteins of interest. Parameters like average
clustering coefficient, topological coefficient, average degree,
power law distribution of degrees and betweenness centrality have
been assessed to capture the topology of the networks. Highly
cohesive networks have been found to be composed of low-degree
nodes (nodes with fewer neighbours) and higher degree nodes are
found to have less connected neighbours. The distribution of
clustering coefficient is an important characteristic of scale-free
networks which decreases as the node degree increases, thereby
following a power law distribution. The clustering coefficient of a
node is always a number between 0 and 1. The average clustering
coefficient characterizes the ‘cliquishness’ of a network. It gives a
measurement of average of clustering coefficients for all the nodes
with at least two neighbours in a network [85]. The value of
average clustering coefficient has been observed to be less in each
of the four sub-networks. Average clustering coefficients along with
average degrees and network densities are shown in Table 2. In
the present analysis the average clustering coefficient and network
density for each sub-network appears to be less as compared to the
average degree (Table 2). The log-log graph of average clustering
coefficient demonstrates that the C(k) decreases as k increases
(Figure 6). Figure 6A demonstrates network TranscriptionFac-
tors_KidneyComplication having the best hierarchical scale free
Figure 5. Wnt_VascularComplication network shows the interaction between mitochondrial fission, ROS, Wnt signaling and VE-
cadherin causing vascular complication (A-B). All the nodes and edges are in green and purple color respectively. The key molecules which are
significantly expressed through their interactions with other molecules in the network are highlighted as orange. The molecules connecting two
portions of the sub-network are colored as grey. The hub molecules are also colored as purple. A. Interaction overview (constructed and analyzed in
Cytoscape): a skeletal view showing only the key interactions where the molecules are shown in orange and the pathological conditions caused by
them are in blue. B. Expanded view of the network imported from Cytoscape: The b-catenin and TGFB centric hubs are connected through 6
molecules i.e., SMAD2 and 4, casein kinases, PIP3K regulatory subunit alpha and TGFBR. DNM1L is connected to the b-catenin hub through GSK-3B.
Interaction of b-catenin with VEGFR2 and subsequent interaction with CDH5 is also illustrated here implying a possible role in kidney complication. It
also displays the interaction between WNK1, SMAD2 and TGFBRII which is observed only in diabetic nephropathy dataset.
doi:10.1371/journal.pone.0008100.g005
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clustering coefficients decline continuously, thereby showing that
these data points fit best to the power line curve. The network
GAPDH-EGFR_MicrovascularComplication (Figure 6B) also
shows a decline in average clustering coefficients, however the
decline is not as smooth and gradual as in the first case as some
points show more deviations from the power line. In the
Wnt_VascularComplication pathway (Figure 6D), initially the
average clustering coefficient points are randomly scattered but as
the number of neighbours increase the average clustering
coefficients begin to decrease. However, in case of the pathway
Akt/Pi3k pathway_VascularDysfunction although the average
clustering coefficients decrease, they are much more scattered
than the rest as shown in Figure 6C. Hence the network is not as
scale free as the remaining networks.
R-squared value is a statistical measure of the linearity of the
curve fit and used to quantify the fit to the power line. It shows the
correlation between the given data points and the corresponding
Figure 6. Average clustering coefficient C(k) of all genes with k links follows the scaling law. The average clustering coefficient C(k) is
plotted on y-axis as a function of number of neighbours (k) on x-axis for the four networks. The graph exhibits a decreasing tendency of C(k) as k
increases. The property follows the power law distribution and shows the nature of scale-free network suggesting a hierarchical organization in the
network. (A-D) display the graphical distribution of the four networks namely, (A) TranscriptionFactors_KidneyComplication (R-squared value 0.94). (B)
GAPDH-EGFR_MicrovascularComplication (R-squared value 0.857). (C) Akt/Pi3k pathway_VascularDysfunction (R-squared value 0.637). (D)
Wnt_VascularComplication (R-squared value 0.787).
doi:10.1371/journal.pone.0008100.g006
Table 2. Topological parameters showing the significance of all the four sub-networks.
Four selected sub-networks Average degree Network density Clustering coefficient
TranscriptionFactors_KidneyComplication 4.2 0.07 0.267
GAPDH-EGFR_MicrovascularComplication 5.25 0.11 0.269
Akt/Pi3k pathway_VascularDysfunction 5.7 0.05 0.242
Wnt_VascularComplication 5.0 0.10 0.247
doi:10.1371/journal.pone.0008100.t002
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variability in a data set which is explained by a fitted linear model.
When the fit is good, the R-squared value is very close to one. The
R-squared values for the average clustering coefficient is highest
for the network TranscriptionFactors_KidneyComplication (0.94)
confirming the observation of best scale free network, followed by
GAPDH-EGFR_MicrovascularComplication (0.857), Wnt_Vas-
cularComplication pathway (0.787) and Akt/Pi3k pathway_Vas-
cularDysfunction (0.631).
In signalling networks hub nodes are thought to play significant
regulatory roles on their adjacent nodes. In such networks the
degree distribution P (k) and the topological coefficient TC(k) are
expected to be inversely proportional to the number of links. The
similar trend is observed in the four networks (Figure 7 and 8) with
R-squared values of degree distribution ranging between 0.5–0.8
(Table 3). The networks follow the power law distribution with
highest R-squared value of 0.778 for TranscriptionFactors_Kid-
neyComplication exhibiting its strongest distribution. As R-
squared values approach unity, it implies that the regression
approaches a perfect fit. Our results are similar to the general
trend with genetic perturbation networks and other gene co-
expression networks exhibiting scale free topology (with R-squared
values above 0.6–0.7) [86,87]. The decrease in topological
coefficients with the increase in number of neighbours explains
that hubs are rather exclusive with rare common neighbours than
individual proteins with fewer links. Figure 8D displays that the
network Wnt_VascularComplication has one well defined hub.
Figures 8A and 8B show that networks TranscriptionFactors_
KidneyComplication and GAPDH-EGFR_MicrovascularCompli-
cation both have two hubs each, which are connected through few
common neighbours. From Figure 8C we observe that the
network Akt/Pi3k pathway_VascularDysfunction also has impor-
tant hubs but there are greater numbers of common neighbours
interacting between the main hubs and therefore the hubs are not
as distinct as in case of the other networks.
Table 3 shows the value of c, the threshold value of betweenness
centrality and degree of nodes for the different networks. The
value of c lies between 1 and 2, which is a characteristic of
biological networks [88]. The betweenness centrality values are
found to be higher than the average value for the hub nodes. The
threshold value of betweenness centrality lies between 55 and 190
for the identified networks. The threshold value for node degree
for the four networks ranges from 4.85 to 6.57. An over-all scale-
free topology is maintained in the four networks. The pattern of
Figure 7. Power law node-degree distribution for the four signature networks. The node degree (k) is represented on the x-axis and the
number of nodes with a particular k is represented on the y-axis. The graph displays a decreasing trend of degree distribution with increase in
number of links displaying scale free topology. (A-D) display the graphical distribution of the four networks namely, (A) TranscriptionFactors_
KidneyComplication (R-squared value 0.778). (B) GAPDH-EGFR_MicrovascularComplication (R-squared value 0.523). (C) Akt/Pi3k pathway_Vascu-
larDysfunction (R-squared value 0.695). (D) Wnt_VascularComplication (R-squared value 0.554).
doi:10.1371/journal.pone.0008100.g007
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free topology. All the information on network topology provides
high confidence to their scale-freeness property supporting the fact
that the underlying model is linear. Therefore, it can be suggested
that the four networks analysed here are sensitive to the
perturbation of more highly connected hubs rather than removal
of less connected nodes. There is a scope to obtain further
improved results since only the positive data points have been
considered for the present analysis.
Gene Ontology (GO) Verification of Sub-Networks
Similarly functioning proteins tend to form clusters of protein-
protein interaction [89]. Sub-networks with overrepresented
functional GO categories have been illustrated in pie diagrams
(Figure S1A-S1D). The size of each section of the pie chart is
basically based on its cluster frequency with statistically significant
p-value that allows better visualization of the functional categories.
We see in the Figure S1, that most of the molecules are involved in
signalling pathways mediated by growth factors, kinases, signal
Table 3. Value of R-square, degree exponent, threshold value of betweenness centrality and node degree of the four networks.











TranscriptionFactors_KidneyComplication 0.778 0.94 1.296 71.67 4.85
GAPDH-EGFR_MicrovascularComplication 0.523 0.857 1.021 57.25 6.0
Akt/Pi3k pathway_VascularDysfunction 0.695 0.631 1.097 188.51 6.57
Wnt_VascularComplication 0.554 0.787 1.076 68.48 5.62
doi:10.1371/journal.pone.0008100.t003
Figure 8. Topological coefficients analysis indicating modular network organization. The distribution of topological coefficient TC (k) is
plotted on y-axis and the number of neighbours is plotted on x-axis. The graph shows gradual decrease of this distribution. (A-D) display the
graphical distribution of the four networks namely, (A) TranscriptionFactors_KidneyComplication. (B) GAPDH-EGFR_MicrovascularComplication. (C)
Akt/Pi3k pathway_VascularDysfunction. (D) Wnt_VascularComplication.
doi:10.1371/journal.pone.0008100.g008
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receptors. Therefore, it can be assumed that the sub-networks
represent the clusters of signalling components, which upon
alteration may cause T2D and its associated complications.
Two Novel Interactions and Their Verification
The two novel interactions put forward here are the interaction
between SUMO4 and GAPDH and the interaction between
GAPDH and EGFR. Analysis of conserved domains for the two
new interactions reveals the following findings. SUMO4 which is a
negative regulator of NF-kB interacts with GAPDH via its ubiquitin
domain. GAPDH is a key enzyme in glycolysis and is found to
regulate insulin and EGFR mediated pathways. Both the
components are found to interact in the network obtained from
Obs_Hs and IR_Hs. The network GAPDH-EGFR_Microvascu-
larComplication was identified on the basis of its significance
score.
SUMO4 shows the presence of ubiquitin domain. Ubiquitination
is an ATP-dependent process which involves the action of three
main enzymes, namely, E1 (ubiquitin activation enzyme), E2
(ubiquitin conjugating enzyme) and E3 (ubiquitin ligase enzyme)
[90,91]. SUMO4 belongs to the SUMO gene family which encodes
small ubiquitin-related modifiers that are attached to proteins and
control the target proteins’ subcellular localization, stability, or
activity.
GAPDH participates in energy yielding processes and is found to
interact with E2 and E3 enzymatic domains. NO-S-nitrosylation-
GAPDH-E3/2 cascade mediates cell death under oxidative stress
conditions and thus represent an important mechanism of
cytotoxicity [92,93,94]. With the help of E3 ligase, ubiquitin is
transferred from E2 enzyme to a lysine residue on a substrate
protein like GAPDH [91].
Ubiquitin-like proteins function as critical regulators of cellular
processes and intracellular stress. The C-terminal glycine residue
of the ubiquitin-related proteins attach to a lysine side chain of the
substrate protein to form an isopeptide linkage [91,95,96]. Thus
we can hypothesize that protein coded by SUMO4 interacts with
the lysine residues in GAPDH and plays a role in regulation of
cellular processes such as transcription, signal transduction, repair,
autophagy and cell cycle control [97].
The interaction between GAPDH and EGFR is predicted using
the application of InterDom [59,60], 3did [61] and ELM [98]. We
predicted the motifs as well as conserved domains in both GAPDH
and EGFR (as shown in Figure S2 and datasets S3 and S4). Motifs
were found out using ELM (Eukaryotic Linear Motif resource).
The interactions between domains were predicted using InterDom
and the interactions between the chosen motifs and domains was
observed using 3did (3D Interacting Domains). The domains and
motifs for SUMO4, GAPDH and EGFR are presented in Datasets
S3 and S4. From InterDom, it has been noted that the protein
tyrosine kinase domain present in EGFR interacts with both C-
terminal and N-terminal domains of GAPDH. This observation
was further validated using 3did, which showed that in the
interaction pattern of GAPDH and EGFR, the protein tyrosine
kinase domain of the latter interacts with GAPDH motifs via SH2/
3_1 domains as illustrated in Figure S2.
Discussion
Network-based analysis provides system level relationship of
molecules across different layers of regulatory controls of biological
functions by integrating functional interactions with co-expression
information. In order to delineate significant observations, the
present study focuses on expression profiles of those interactions/
associations, which existed most consistently in maximum number
of microarray datasets. The analysis and literature on different
biological processes offer an insight into the identification of
several facts associated with T2D. Our approach may serve as
predictive tool for identifying underlying novel pathways and
disease mechanisms in the development of other T2D complica-
tions and may also prove useful in providing insight in etiology and
progression of other diseases.
A distinct scale-freeness property has been noticed in the four
sub-networks as they have decreasing values of coefficients for
some topological parameters like average degree, average
clustering coefficient and topological coefficient. Simultaneously,
betweenness centrality value, another significant topology identi-
fying parameter describes the presence of few important hubs with
other nodes. The Wnt_VascularComplication sub-network shows
the presence of two distinct hubs, while Akt/Pi3k pathway_Vas-
cularDysfunction sub-network displays more hubs with greater
number of common neighbours. Betweenness centrality calculates
the effectiveness of nodes communicating with other nodes in the
sub-network. It is suggested that higher the betweenness value of a
node, the higher its significance because a protein with higher
degree is more likely to be essential since it has more links.
Therefore, threshold betweenness value higher than its average
value suggests the importance of the interacting sub-network
depending on its nodes’ connectivities. All these properties reflect
the hierarchical organization and scale-free nature of these sub-
networks.
The TranscriptionFactors_KidneyComplication sub-sub-net-
work observed from diabetes, obesity and PCOD datasets suggests
a common pathway for causing impaired insulin signalling and
generating vascular complications through the interaction between
pathways mediated by growth related proto-oncogenes and GCR.
The sub-network illustrates that increased FFA linked with GCR
plays a pivotal role in progression of T2D. High amount of FFA
has been reported to be associated with diabetes and its
complications. FFA is elevated in insulin-resistant subjects because
of impaired insulin-dependent down-regulation of lipolysis.
Increased FFAs competitively inhibit oxidation of glucose,
contributing to the development of insulin resistance [63] and
also affect ROS generation thereby acting as source of oxidative
stress [99]. GC may increase circulating FFA by inhibiting
lipoprotein lipase and thereby increase both the uptake and
turnover of fatty acids in adipose tissue. Effect of GC includes
impaired insulin-dependent glucose uptake in the periphery and
enhanced gluconeogenesis in the liver leading to insulin resistance
[63,64]. The TranscriptionFactors_KidneyComplication sub-net-
work reveals up regulation of GCR. Increased GCR sensitivity can
be considered as an indicator of excessive activity of GC which is a
plausible contributor to obesity and insulin resistance. FFA induces
the over-expression of TGFBRII as noted in diabetic kidney disease
[100] and it increases the expressions of proto-oncogenes and
SMAD3 in TGFB signalling process [101]. TGFB induces as well as
gets activated by ROS intermediates [102,65]. ROS stimulates
early growth signals including induction of c-Fos and c-Myc mRNA
expression via TGFB signalling [103]. Growth related proto-
oncogenes exhibit high expression in early phase of glomerular
hypertrophy during hyperglycemia [104,105]. Literature also
reports that systemic short chain fatty acids can up regulate the
expression of early response genes such as c-Myc, c-Fos and c-Jun
[106]. These genes can bind to the (AP)-1 sites of the promoters of
their target genes like fibronectin and result in their differential
transcription [66]. Moreover, the over-expression of TGFBRII
during high glucose concentration leads to an increase in
expression of type 1 collagen and accumulation of extra cellular
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characteristic of fibrosis [108,109]. We hypothesize that such an
association involving FFA, TGFB-TGFBRII and proto-oncogenes
could eventually lead to fibrosis of renal cells when glucose
concentration is high. This sub-network shows the existence of
considerable number of genes playing roles in signal transduction,
positive regulation of transcription and regulation of cell cycle
through gene ontology analysis. It also displays the involvement of
genes in molecular functions like protein serine/threonine kinase
activity and TGFBR activity.
Sub-network from obesity and diabetes datasets indicate the
significant roles of SUMO4, GAPDH and EGFR interactions in
insulin signalling diabetes progression. From the information
gathered regarding their individual functions, we propose that
under conditions of stress and obesity, the interactions between
SUMO4 and GAPDH play a role in regulating insulin and EGFR
signalling to increase vascular complications in diabetic subjects.
In diabetes, ubiquitin/proteasome over activity is associated with
enhanced inflammatory activity induced by oxidative stress. In
response to FFA, SUMO4 is capable of inducing the expression of
inflammatory cytokines which target vessels and kidney in
cardiovascular and renal diseases. The variants of SUMO4 have
been reported to be associated with T2D and diabetic
nephropathy via the induction of NF-kB pathway. SUMO4 gene
encodes small ubiquitin like modifier 4, which alters immune
response through IkBa, and regulates NF-kB activation [110,111].
GAPDH over-expression may be attributed to compensate for the
progressive decrease in muscle mitochondrial function due to
FFA induced ROS and contribute to loss of glucose and lipid
homeostasis and eventually obesity and T2D [112,113]. GAPDH
can mediate cell death associated with oxidative stress [92]. Our
sub-network displays SUMO4 and EGFR interacting with
GAPDH. Interaction between GAPDH and SUMO4 suggests that
they may be interacting together through ubiquitination process.
It is inferred from literature that GAPDH (lys) can interact with
ubiquitin ligase enzyme (E3) and form an isopeptide bond with
the C-terminal glycine motifs of SUMO4 [91,93]. In the
interaction pattern of GAPDH and EGFR, the protein tyrosine
kinase domain of the latter has been predicted to interact with
GAPDH. Therefore, it can be envisaged that GAPDH is getting
phosphorylated by EGFR tyrosine kinase. These interactions
were verified using 3did and Interdom (Figure S2 and Datasets
S3 and S4) and suggest a role in the progression of T2D
accompanied with obesity. GAPDH-EGFR_MicrovascularCom-
plication sub-network further displays interaction between EGFR
and 14-3-3 zeta. Up regulation of EGFR has been reported to
cause vascular complications in diabetic rodent models
[114,115]. Proteins belonging to the 14-3-3 family are involved
in metabolism, cell survival and proliferation [116]. Association
of IRS-1 with 14-3-3 protein is reported to play a role in the
regulation of insulin sensitivity by interrupting the interaction
b e t w e e nt h ei n s u l i nr e c e p t o ra n dIRS [117]. Thus we deduce that
EGFR can interact with IRS-1 via 14-3-3 zeta and result in
impaired insulin signalling. It has been reported that agents such
as FFAs, cytokines, cellular stress and hyperinsulinemia, induce
insulin resistance, and lead to activation of several serine/
threonine kinases and phosphorylation of IRS-1 as well. These
agents negatively regulate IRS-1 functions by phosphorylation
[118]. Gene ontology analysis of this sub-network establishes its
enrichment with signal transduction, phosphorylation and
signalling pathway mediated by insulin receptor. Molecular
functions like protein kinase and MAPK activities and EGFR
activity have been found to be associated with significant number
of genes from the sub-network.
Sub-network from diabetic nephropathy datasets exhibits
increased expression of AKT1 which gets accumulated in diabetic
kidneys. This gene mediates insulin signalling by inducing PI3-K.
On the other hand, up-regulation of EGFR has been observed to
activate AKT1 [72]. Protein coded by PTPN1, a tyrosine
phosphatase kinase gene is a negative regulator of insulin signalling
and has been reported to be associated with diabetes mellitus
[119,73]. This gene has been identified as a potential drug target
for treating obesity and T2D [120]. PTPN1 has been observed to
interact with EGFR in the present sub-network. Signalling pathway
mediated by EGFR plays central role in regulating numerous other
signalling pathways. The phosphatise activity of PTPN1 has been
shown to regulate many incoming and outgoing signals to EGFR
[74]. Subsequently, the interplay between PTPN1 and CAV1 has
been noted here. Studies show that PTPN1 has a binding site for
CAV1. The association has been found to modulate the activity of
PTPN1 [121]. Up-regulation of CAV1 has been found to
contribute to the development of T2D [75]. Protein coded by
CAV1 is known to be involved in signal transduction and many
cellular processes. It has been observed that the scaffolding domain
of the protein coded by CAV1 binds directly to the insulin receptor
thereby regulating glucose homeostasis [122]. Analysis of gene
ontology exhibits the gene abundance, which play a significant
role in processes such as insulin receptor signalling, cytoskeletal
protein binding. Considerable numbers of genes participate in
molecular functions like protein tyrosine kinase activity and EGFR
activity. From this diabetic nephropathy sub-network module we
have proposed the two putative interactions of PTPN1 with EGFR
and CAV1 which have been highlighted for the first time in
diabetes condition.
A common trend across the sub-network Wnt_VascularCom-
plication describes the significance of oxidative stress modulating
Wnt/b-catenin and CDH5 in diabetes. Oxidative stress produced by
the overproduction of ROS depends on mitochondrial morphol-
ogy and plays a major role in beta-cell dysfunction, insulin
resistance, glucose intolerance and above all, T2D [76,123]. Genes
involved in oxidative stress like FIS1 and DNM1L are shown to
modulate Wnt signalling via GSK-3B. Both DNM1L and FIS1 are
involved in the maintenance of mitochondrial morphology, which
regulates molecules of Wnt signalling pathway like b-catenin and
GSK-3B [124,125]. It exists in two isoforms i.e., alpha (GSK-3A)
and beta (GSK-3B) which are coded by two separate genes.
Elevated level of GSK-3B has been observed to contribute to
diabetes development. Targeting and synthesizing selective
inhibitors of this molecule have been shown to modulate insulin
sensitivity [126].This gene eventually has been reported to interact
with b-catenin [78]. b-catenin serves as a substrate of GSK-3B by
phosphorylation. Over-expression of GSK-3B increases the
phosphorylation of b-catenin resulting in the formation of a
cytoplasmic multi-protein complex. This induces the degradation
of b-catenin in a proteosomal pathway [77,78]. The association
between CDH5 and b-catenin suggests their involvement in the
pathogenesis of T2D. The interactions of b-catenin with CDH5
and TGFBRI have been noted from exclusively diabetes mellitus
dataset and also from diabetic nephropathy dataset. The protein
coded by CDH5 has been specifically found to express in vascular
endothelial cells. b-catenin has been found to interact with CDH5
in cell adhesion. It is strongly suggested that signalling mediated by
b-catenin modulates the organization and function of endothelial
cells. Degradation of this protein might impair the growth of
endothelial cells [127]. Therefore, we propose that the association
of CDH5 with b-catenin might play a significant role in diabetes
mellitus through the impairment of vascular endothelial cell
function. Gene ontology analysis of this sub-network module
Network Biology
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signal transduction, phosphorylation and positive regulation of
transcription. Molecular functions such as signal transducer
activity and protein kinase cascade activity has also been related
with several genes from the sub-network. An intensive biochemical
analysis on these interactions can bring more insight into the
understanding of their causal relationships in T2D. Therefore,
there is a wide scope to analyze further these interactions which
could probably render into the development of new gene/protein
targets eventually leading to the development of therapeutic drugs.
Supporting Information
Figure S1 Over-representation of gene ontology categories from
the four selected sub-networks (A-D): The enrichment of
significant GO terms (biological processes and molecular func-
tions) with the genes present in the networks. Each GO category
has been calculated using the percent frequency of that category
enriched with nodes. (A). Illustrates the GO categories for the
network TranscriptionFactors_KidneyComplication showing the
significance of signal transduction, regulation of cell cycle and
positive regulation of transcription. (B). The network GAPDH-
EGFR_MicrovascularComplication showing greater enrichment
of categories signal transduction and phosphorylation than the
others. (C). Exhibits the major distribution of biological processes
like apoptosis and insulin receptor signalling pathway from the
network Akt/Pi3k pathway_VascularDysfunction. (D). Shows the
distribution of GO categories for the sub-network Wnt_Vascu-
larComplication. The categories of signal transduction, phosphor-
ylation and positive regulation of transcription show maximum
enrichment suggesting that majority of genes participate in
signalling pathways and phosphorylation processes.
Found at: doi:10.1371/journal.pone.0008100.s001 (0.78 MB TIF)
Figure S2 Interaction between EGFR and GAPDH through
Protein Tyrosine Kinase domain of EGFR and motifs of GAPDH:
Protein Tyrosine Kinase domain of EGFR interacts with C-
terminal and N-terminal domains of GAPDH. Information on
motifs for the genes, was got using Eukaryotic Linear Motif resource
(ELM). The interaction between the motifs (LIG_SH2_SRC,
LIG_SH2_STAT5 and LIG_SH3_3) of GAPDH and EGFR can
be visualised using 3did. The interaction with Protein Tyrosine
Kinase domain takes place via SH2/3_1 domains.
Found at: doi:10.1371/journal.pone.0008100.s002 (1.02 MB TIF)
Dataset S1 Details of the datasets on their tissue source, control
sets and diseased sets.
Found at: doi:10.1371/journal.pone.0008100.s003 (0.03 MB
DOC)
Dataset S2 Statistically determined up-regulated and down-
regulated genes from microarray studies.
Found at: doi:10.1371/journal.pone.0008100.s004 (0.03 MB
DOC)
Dataset S3 Interacting domains for SUMO4, GAPDH and
EGFR.
Found at: doi:10.1371/journal.pone.0008100.s005 (0.03 MB
DOC)
Dataset S4 List of interacting motifs for SUMO4, GAPDH and
EGFR.
Found at: doi:10.1371/journal.pone.0008100.s006 (0.07 MB
DOC)
Acknowledgments
We are grateful to Prof. N. Yathindra (IBAB) for all his encouragement and
support throughout the course of this work.
Author Contributions
Conceived and designed the experiments: ND SA. Analyzed the data: US
SU SA. Wrote the paper: US SU SA.
References
1. Ramachandran A, Snehalatha C, Viswanathan V (2002) Burden of type 2
diabetes and its complications- The Indian scenario. Current Science 83:
1471–1476.
2. Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Me ´deau V, et al. (2008)
Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes
Metabolism 34: S43–48.
3. Baudry A, Leroux L, Jackerott M, Joshi RL (2002) Genetic manipulation of
insulin signalling, action and secretion in mice. Insights into glucose
homeostasis and pathogenesis of type 2 diabetes. EMBO Rep 3: 323–328.
4. Mazzone T, Chait A, Plutzky J (2008) Cardiovascular disease risk in type 2
diabetes mellitus: insights from mechanistic studies. Lancet 371: 1800–1809.
5. Bhattacharya S, Mandal SK, Bandyopadhyay R, Chakrabarti S, Basu AK, et
al. (2007) A study on nephropathy in type 2 diabetes mellitus: histology and its
correlation with clinical and biochemical parameters. J Indian Med Assoc 105:
592, 594–596.
6. Schwartz MM, Lewis EJ, Leonard-Martin T, Lewis JB, Batlle D (1998)
Renal pathology patterns in type II diabetes mellitus: relationship with
retinopathy. The Collaborative Study Group. Nephrol Dial Transplant 13:
2547–2552.
7. Janghorbani M, Rezvanian H, Kachooei A, Ghorbani A, Chitsaz A, et al.
(2006) Peripheral neuropathy in type 2 diabetes mellitus in Isfahan, Iran:
prevalence and risk factors. Acta Neurol Scand 114: 384–391.
8. Jbour AS, Jarrah NS, Radaideh AM, Shegem NS, Bader IM, et al. (2003)
Prevalence and predictors of diabetic foot syndrome in type 2 diabetes mellitus
in Jordan. Saudi Med J 24: 761–764.
9. Bray GA, Jablonski KA, Fujimoto WY, Barrett-Connor E, Haffner S, et al.
(2008) Rela$tion of central adiposity and body mass index to the development
of diabetes in the Diabetes Prevention Program. Am J Clin Nutr 87:
1212–1218.
10. Kraegen EW, Cooney GJ (2008) Free fatty acids and skeletal muscle insulin
resistance. Curr Opin Lipidol 19: 235–241.
11. Boden G (2008) Obesity and free fatty acids. Endocrinol Metab Clin North Am
37: 635–646, viii–ix.
12. Shah A, Mehta N, Reilly MP (2008) Adipose inflammation, insulin resistance,
and cardiovascular disease. JPEN J Parenter Enteral Nutr 32: 638–644.
13. Bouskela E, Kraemer de Aguiar LG, Nivoit P, Bahia LR, Villela NR, et al.
(2007) Vascular dysfunction in metabolic disorders: evaluation of some
therapeutic interventions. Bull Acad Natl Med 191: 475–492.
14. Gogg S, Smith U (2002) Epidermal growth factor and transforming growth
factor alpha mimic the effects of insulin in human fat cells and augment
downstream signalling in insulin resistance. J Biol Chem 277: 36045–36051.
15. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC (2006) Role of the
JAK/STAT signalling pathway in diabetic nephropathy. Am J Physiol Renal
Physiol 290: F762–768.
16. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB (2002) Inhibition of the
Jak/STAT signalling pathway prevents the high glucose-induced increase in
tgf-beta and fibronectin synthesis in mesangial cells. Diabetes 51: 3505–3509.
17. Adhikary L, Chow F, Nikolic-Paterson DJ, Stambe C, Dowling J, et al. (2004)
Abnormal p38 mitogen-activated protein kinase signalling in human and
experimental diabetic nephropathy. Diabetologia 47: 1210–1222.
18. Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M (2005) Increased
vascular endothelial growth factor expression but impaired vascular endothelial
growth factor receptor signalling in the myocardium of type 2 diabetic patients
with chronic coronary heart disease. J Am Coll Cardiol 46: 827–834.
19. Das UN, Rao AA (2007) Gene expression profile in obesity and type 2 diabetes
mellitus. Lipids Health Dis 6: 35.
20. Burgermeister E, Seger R (2007) MAPK kinases as nucleo-cytoplasmic shuttles
for PPARgamma. Cell Cycle 6: 1539–1548.
21. Jiang G, Zhang BB (2002) Pi 3-kinase and its up- and down-stream modulators
as potential targets for the treatment of type II diabetes. Front Biosci 7:
d903–907.
22. Rulifson IC, Karnik SK, Heiser PW, ten Berge D, Chen H, et al. (2007) Wnt
signalling regulates pancreatic beta cell proliferation. Proc Natl Acad Sci U S A
104: 6247–6252.
23. Ho E, Bray TM (1999) Antioxidants, NFkappaB activation, and diabetogenesis.
Proc Soc Exp Biol Med 222: 205–213.
Network Biology
PLoS ONE | www.plosone.org 15 December 2009 | Volume 4 | Issue 12 | e810024. Zhao J, Zhang N, He M, Yang Z, Tong W, et al. (2008) Increased beta-cell
apoptosis and impaired insulin signalling pathway contributes to the onset of
diabetes in OLETF rats. Cell Physiol Biochem 21: 445–454.
25. Hadi HA, Suwaidi JA (2007) Endothelial dysfunction in diabetes mellitus. Vasc
Health Risk Manag 3: 853–876.
26. Aggarwal A, Guo DL, Hoshida Y, Yuen ST, Chu KM, et al. (2006)
Topological and functional discovery in a gene coexpression meta-network of
gastric cancer. Cancer Res 66: 232–241.
27. Chu LH, Chen BS (2008) Construction of a cancer-perturbed protein-protein
interaction network for discovery of apoptosis drug targets. BMC Syst Biol 2:
56.
28. Rasche A, Al-Hasani H, Herwig R (2008) Meta-Analysis Approach identifies
Candidate Genes and associated Molecular Networks for Type-2 Diabetes
Mellitus. BMC Genomics 9: 310.
29. Liu M, Liberzon A, Kong SW, Lai WR, Park PJ, et al. (2007) Network-based
analysis of affected biological processes in type 2 diabetes models. PLoS Genet
3: e96.
30. Bergholdt R, Størling ZM, Lage K, Karlberg EO, Olason PI, et al. (2007)
Integrative analysis for finding genes and networks involved in diabetes and
other complex diseases. Genome Biol 8: R253.
31. Tornow S, Mewes HW (2003) Functional modules by relating protein
interaction networks and gene expression. Nuc. Acids Res 31: 6283–6289.
32. Marcotte EM, Pellegrini M, Thompson MJ, Yeates TO, Eisenberg D (1999) A
combined algorithm for genome-wide prediction of protein function. Nature
402: 83–6.
33. Begley TJ, Rosenbach AS, Ideker T, Samson LD (2002) Damage Recovery
Pathways in Saccharomyces cerevisiae Revealed by Genomic Phenotyping and
Interactome Mapping. Molecular Cancer Reseacrch 1: 103–112.
34. Yang X, Pratley RE, Tokraks S, Bogardus C, Permana PA (2002) Microarray
profiling of skeletal muscle tissues from equally obese, non-diabetic insulin-
sensitive and insulin-resistant Pima Indians. Diabetologia 45: 1584–1593.
35. Nair S, Lee YH, Rousseau E, Cam M, Tataranni PA, et al. (2005) Increased
expression of inflammation-related genes in cultured preadipocytes/stromal
vascular cells from obese compared with non-obese Pima Indians. Diabetologia
48: 1784–1788.
36. Lee YH, Nair S, Rousseau E, Allison DB, Page GP, et al. (2005) Microarray
profiling of isolated abdominal subcutaneous adipocytes from obese vs non-
obese Pima Indians: increased expression of inflammation-related genes.
Diabetologia 48: 1776–1783.
37. Park JJ, Berggren JR, Hulver MW, Houmard JA, Hoffman EP (2006) GRB14,
GPD1, and GDF8 as potential network collaborators in weight loss-induced
improvements in insulin action in human skeletal muscle. Physiol Genomics 27:
114–121.
38. Corto ´n M, Botella-Carretero JI, Bengurı ´a A, Villuendas G, Zaballos A, et al.
(2007) Differential gene expression profile in omental adipose tissue in women
with polycystic ovary syndrome. J Clin Endocrinol Metab 92: 328–337.
39. Baelde HJ, Eikmans M, Doran PP, Lappin DW, de Heer E, Bruijn JA (2004)
Gene expression profiling in glomeruli from human kidneys with diabetic
nephropathy. Am J Kidney Dis 43: 636–650.
40. Mishra R, Emancipator SN, Miller C, Kern T, Simonson MS (2004) Adipose
differentiation-related protein and regulators of lipid homeostasis identified by
gene expression profiling in the murine db/db diabetic kidney. Am J Physiol
Renal Physiol 286: F913–921.
41. Patti ME, Butte AJ, Crunkhorn S, Cusi K, Berria R, et al. (2003) Coordinated
reduction of genes of oxidative metabolism in humans with insulin resistance
and diabetes: Potential role of PGC1 and NRF1. Proc Natl Acad Sci U S A
100: 8466–8471.
42. Li C, Wong W (2003) DNA-chip analyzer (dChip). In: Parmigiani G,
Garrett ES, Irizarry R, Zegar SL, eds.The Analysis of Gene Expression Data:
Methods and Software. New York: Springer, NY. pp 120–141.
43. Hernandez-Toro J, Prieto C, De las Rivas J (2007) APID2NET: unified
interactome graphic analyzer. Bioinformatics 23: 2495–2497.
44. Xenarios I, Rice DW, Salwinski L, Baron MK, Marcotte EM, et al. (2000) DIP:
the database of interacting proteins. Nucleic Acids Res 28: 289–291.
45. Bader GD, Betel D, Hogue CW (2003) BIND: the Biomolecular Interaction
Network Database. Nucleic Acids Res 31: 248–250.
46. Hermjakob H, Montecchi-Palazzi L, Lewington C, Mudali S, Kerrien S, et al.
(2004) IntAct: an open source molecular interaction database. Nucleic Acids
Res 32: D452–455.
47. Chatr-aryamontri A, Ceol A, Palazzi LM, Nardelli G, Schneider MV, et al.
(2007) MINT: the Molecular INTeraction database. Nucleic Acids Res 35:
D572–574.
48. Peri S, Navarro JD, Kristiansen TZ, Amanchy R, Surendranath V, et al. (2004)
Human protein reference database as a discovery resource for proteomics.
Nucleic Acids Res 32: D497–501.
49. Prieto C, De Las Rivas J (2006) APID: Agile Protein Interaction DataAnalyzer.
Nucleic Acids Res 34: W298–302.
50. Ng A, Bursteinas B, Gao Q, Mollison E, Zvelebil M (2006) pSTIING: a
‘systems’ approach towards integrating signalling pathways, interaction and
transcriptional regulatory networks in inflammation and cancer. Nucleic Acids
Res 34: D527–534.
51. Assenov Y, Ramı ´rez F, Schelhorn SE, Lengauer T, Albrecht M (2008)
Computing topological parameters of biological networks. Bioinformatics 24:
282–284.
52. Scardoni G, Petterlini M, Laudanna C (2008) CentiScaPe, a Cytoscape plugin
for network centralities. Center for BioMedical Computing (CBMC),
University of Verona, Italy. Available: http://profs.sci.univr.it/,scardoni/
centiscape/centiscapepage.php.
53. Weisstein E. W. Least Squares Fitting - Power Law. MathWorld - A
Wolfram Web Resource. Available: (http://mathworld.wolfram.com/
LeastSquaresFittingPowerLaw.html).
54. Zhang B, Horvath S (2005) A general framework for weighted gene co-
expression network analysis. Stat Appl Genet Mol Biol 4.
55. Estrada E (2006) Virtual identification of essential proteins within the protein
interaction network of yeast. Proteomics 6: 35–40.
56. Barabasi AL, Albert R (1999) Emergence of scaling in random networks.
Science 286: 509–512.
57. Jeong H, Mason SP, Baraba ´si AL, Oltvai ZN (2001) Lethality and centrality in
protein networks. Nature 411: 41–42.
58. Garcia O, Saveanu C, Cline M, Fromont-Racine M, Jacquier A (2007)
GOlorize: a Cytoscape plug-in for network visualization with Gene Ontology-
based layout and coloring. Bioinformatics 23: 394–396.
59. Ng SK, Zhang Z, Tan SH, Lin K, et al. (2003) InterDom: a database of
putative interacting protein domains for validating predicted protein interac-
tions and complexes. Nucleic Acids Res 31: 251–254.
60. Ng SK, Zhang Z, Tan SH (2003) Integrative approach for computationally
inferring protein domain interactions. Bioinformatics 19: 923–929.
61. Stein A, Russell RB, Aloy P (2005) 3did: interacting protein domains of known
three-dimensional structure. Nucleic Acids Res 33: D413–417.
62. Whorwood CB, Donovan SJ, Flanagan D, Phillips DI, Byrne CD (2002)
Increased glucocorticoid receptor expression in human skeletal muscle cells
may contribute to the pathogenesis of the metabolic syndrome. Diabetes 51:
1066–1075.
63. Macfarlane DP, Forbes S, Walker BR (2008) Glucocorticoids and fatty acid
metabolism in humans: fuelling fat redistribution in the metabolic syndrome.
Journal of Endocrinology 197: 189–204.
64. Andrews RC, Walker BR (1999) Glucocorticoids and insulin resistance: old
hormones, new targets. Clinical Science 96: 513–523.
65. Ruiz-Ortega M, Rodrı ´guez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J
(2007) TGF-b signalling in vascular fibrosis. Cardiovascular Research 74:
196–206.
66. Xiaoping Luo, Li Ding, Nasser Chegini (2004) Gonadotropin-releasing
hormone and TGF-b activate MAP kinase and differentially regulate
fibronectin expression in endometrial epithelial and stromal cells. Am J Physiol
Endocrinol Metab 287: E991–1001.
67. Sayed-Ahmed N, Besbas N, Mundy J, Muchaneta-Kubara E, Cope G, et al.
(1996) Up regulation of epidermal growth factor and its receptor in the kidneys
of rats with streptozotocin-induced diabetes. Exp Nephrol 4: 330–339.
68. Konishi A, Berk BC (2003) Epidermal growth factor receptor transactivation is
regulated by glucose in vascular smooth muscle cells. J Biol Chem 278:
35049–35056.
69. Shen W, Brown NS, Finn PF, Dice JF, Franch HA (2005) Akt and Mammalian
Target of Rapamycin Regulate Separate Systems of Proteolysis in Renal
Tubular Cells. J Am Soc Nephrol 17: 2414–2423.
70. Oksvold MP, Huitfeldt HS, Langdon WY (2004) Identification of 14-3-3zeta as
an EGF receptor interacting protein. FEBS Lett 569: 207–210.
71. Marks JB, Raskin P (1998) Nephropathy and hypertension in diabetes. Med
Clin North Am 82: 877–907.
72. Wu D, Peng F, Zhang B, Ingram AJ, Gao B, et al. (2007) Collagen I induction
by high glucose levels is mediated by epidermal growth factor receptor and
phosphoinositide 3-kinase/Akt signalling in mesangial cells. Diabetologia 50:
2008–2018.
73. Bento JL, Palmer ND, Mychaleckyj JC, Lange LA, Langefeld CD, et al. (2004)
Association of protein tyrosine phosphatase 1B gene polymorphisms with type 2
diabetes. Diabetes 53: 3007–3012.
74. McCole DF, Truong A, Bunz M, Barrett KE (2007) Consequences of direct
versus indirect activation of epidermal growth factor receptor in intestinal
epithelial cells are dictated by protein-tyrosine phosphatase 1B. J Biol Chem
282: 13303–13315.
75. Catala ´n V, Go ´mez-Ambrosi J, Rodrı ´guez A, Silva C, Rotellar F (2008)
Expression of caveolin-1 in human adipose tissue is upregulated in obesity and
obesity-associated type 2 diabetes mellitus and related to inflammation. Clin
Endocrinol (Oxf) 68: 213–219.
76. Yu T, Fox RJ, Burwell LS, Yoon Y (2005) Regulation of mitochondrial fission
and apoptosis by the mitochondrial outer membrane protein hFis1. J Cell Sci
118: 4141–4151.
77. Lee S, Jeong SY, Lim WC, Kim S, Park YY, et al. (2007) Mitochondrial fission
and fusion mediators, hFis1 and OPA1, modulate cellular senescence. J Biol
Chem 282: 22977–22983.
78. Hong YR, Chen CH, Cheng DS, Howng SL, Chow CC (1998) Human
dynamin-like protein interacts with the glycogen synthase kinase 3beta.
Biochem Biophys Res Commun 249: 697–703.
79. Hinoi T, Yamamoto H, Kishida M, Takada S, Kishida S, et al. (2000)
Complex formation of adenomatous polyposis coli gene product and axin
facilitates glycogen synthase kinase-3 beta-dependent phosphorylation of beta-
catenin and down-regulates beta-catenin. J Biol Chem 275: 34399–34406.
Network Biology
PLoS ONE | www.plosone.org 16 December 2009 | Volume 4 | Issue 12 | e810080. Caspi M, Zilberberg A, Eldar-Finkelman H, Rosin-Arbesfeld R (2008) Nuclear
GSK-3beta inhibits the canonical Wnt signalling pathway in a beta-catenin
phosphorylation-independent manner. Oncogene 27: 3546–3555.
81. Lin CL, Cheng H, Tung CW, Huang WJ, Chang PJ, et al. (2008) Simvastatin
reverses high glucose-induced apoptosis of mesangial cells via modulation of
Wnt pathway. Am J Nephrol 28: 290–297.
82. Koga H, Sugiyama S, Kugiyama K, Watanabe K, Fukushima H, et al. (2005)
Elevated levels of VE-cadherin-positive endothelial microparticles in patients
with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol 45:
1622–1630.
83. Sato H, Iwano M, Akai Y, Kurioka H, Kubo A, et al. (1998) Increased
excretion of urinary transforming growth factor beta 1 in patients with diabetic
nephropathy. Am J Nephrol 18: 490–494.
84. Tian YC, Phillips AO (2002) Interaction between the transforming growth
factor-beta type II receptor/Smad pathway and beta-catenin during trans-
forming growth factor-beta1-mediated adherens junction disassembly.
Am J Pathol 160: 1619–1628.
85. Friedel CC, Zimmer R (2006) Inferring topology from clustering coefficients in
protein-protein interaction networks. BMC Bioinformatics 7: 519.
86. Carlson MR, Zhang B, Fang Z, Mischel PS, Horvath S, et al. (2006) Gene
connectivity, function, and sequence conservation: predictions from modular
yeast co-expression networks. BMC Genomics 7: 40.
87. Wei H, Persson S, Mehta T, Srinivasasainagendra V, Chen L, et al. (2006)
Transcriptional coordination of the metabolic network in Arabidopsis. Plant
Physiol 142: 762–774.
88. Chung F, Lu L, Dewey TG, Galas DJ (2003) Duplication models for biological
networks. J Comput Biol 10: 677–687.
89. Stelzl U, Worm U, Lalowski M, Haenig C, Brembeck FH, et al. (2005) A
human protein-protein interaction network: a resource for annotating the
proteome. Cell 122: 957–968.
90. Burger AM, Seth AK (2004) The ubiquitin-mediated protein degradation
pathway in cancer: therapeutic implications. Eur J Cancer 40: 2217–2229.
91. Passmore LA, Barford D (2004) Getting into position: the catalytic mechanisms
of protein ubiquitylation. Biochem J 379: 513–525.
92. Hara MR, Cascio MB, Sawa A (2006) GAPDH as a sensor of NO stress.
Biochim Biophys Acta 1762: 502–509.
93. Jenkins JL, Tanner JJ (2006) High-resolution structure of human D-
glyceraldehyde-3-phosphate dehydrogenase. Acta Crystallogr D Biol Crystal-
logr 62: 290–301.
94. Hara MR, Agrawal N, Kim SF, Cascio MB, Fujimuro M, et al. (2005) S-
nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation
following Siah1 binding. Nat Cell Biol 7: 665–674.
95. Wei W, Yang P, Pang J, Zhang S, Wang Y, et al. (2008) A stress-dependent
SUMO4 sumoylation of its substrate proteins. Biochem Biophys Res Commun
375: 454–459.
96. Owerbach D, McKay EM, Yeh ET, Gabbay KH, Bohren KM (2005) A
proline-90 residue unique to SUMO-4 prevents maturation and sumoylation.
Biochem Biophys Res Commun 337: 517–520.
97. Kerscher O, Felberbaum R, Hochstrasser M (2006) Modification of proteins by
ubiquitin and ubiquitin-like proteins. Annu Rev Cell Dev Biol 22: 159–180.
98. Puntervoll P, Linding R, Gemu ¨nd C, Chabanis-Davidson S, Mattingsdal M, et
al. (2003) ELM server: A new resource for investigating short functional sites in
modular eukaryotic proteins. Nucleic Acids Res 31: 3625–3630.
99. Inoguchi T, Li P, Umeda F, Yu HY, Kakimoto M, et al. (2009) High Glucose
Level and Free Fatty Acid Stimulate Reactive Oxygen Species Production
Through Protein Kinase C–Dependent Activation of NAD(P)H Oxidase in
Cultured Vascular Cells. Diabetes 49: 1939–1945.
100. McKnight AJ, Savage DA, Patterson CC, Sadlier D, Maxwell AP (2007)
Resequencing of genes for transforming growth factor beta1 (TGFB1) type 1
and 2 receptors (TGFBR1, TGFBR2), and association analysis of variants with
diabetic nephropathy. BMC Med Genet 8: 5.
101. Okazaki Y, Yamasaki Y, Uchida HA, Okamoto K, Satoh M, et al. (2007)
Enhanced TGF-beta/Smad signalling in the early stage of diabetic nephrop-
athy is independent of the AT1a receptor. Clin Exp Nephrol 11: 77–87.
102. Annes JP, Munger JS, Rifkin DB (2003) Making sense of latent TGFb
activation. Journal of Cell Science 116: 217–224.
103. Rao GN, Lasse ´gue B, Griendling KK, Alexander RW, Berk BC (1993)
Hydrogen peroxide-induced c-fos expression is mediated by arachidonic acid
release: role of protein kinase C. Nucleic Acids Research 21: 1259–1263.
104. Shankland SJ, Scholey JW (1995) Expression of growth-related protooncogenes
during diabetic renal hypertrophy. Kidney International 47: 782–788.
105. Mao CP, Gu ZL (2005) Puerarin reduces increased c-fos, c-jun, and type IV
collagen expression caused by high glucose in glomerular mesangial cells. Acta
Pharmacol Sin 26: 982–986.
106. Tappenden KA, McBurney MI (1998) Systemic short-chain fatty acids rapidly
alter gastrointestinal structure, function, and expression of early response genes.
Digestive Diseases and Sciences 43: 1526–1536.
107. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, et al. (2001)
Increased Glomerular and Tubular Expression of Transforming Growth
Factor-b1, Its Type II Receptor, and Activation of the Smad Signalling
Pathway in the db/db Mouse. Am J Pathol 158: 1653–1663.
108. Wynn TA (2008) Cellular and molecular mechanisms of fibrosis. J Pathol 214:
199–210.
109. Ban CR, Twigg SM (2008) Fibrosis in diabetes complications: pathogenic
mechanisms and circulating and urinary markers. Vasc Health Risk Manag 4:
575–596.
110. Noso S, Fujisawa T, Kawabata Y, Asano K, Hiromine Y, et al. (2007)
Association of small ubiquitin-like modifier 4 (SUMO4) variant, located in
IDDM5 locus, with type 2 diabetes in the Japanese population. J Clin
Endocrinol Metab 92: 2358–2362.
111. Lin HY, Wang CL, Hsiao PJ, Lu YC, Chen SY, et al. (2007) SUMO4 M55V
variant is associated with diabetic nephropathy in type 2 diabetes. Diabetes 56:
1177–1180.
112. Hittel DS, Hathout Y, Hoffman EP, Houmard JA (2005) Proteome Analysis of
Skeletal Muscle From Obese and Morbidly Obese Women. Diabetes 54:
1283–1288.
113. Simoneau JA, Veerkamp JH, Turcotte LP, Kelley DE (1999) Markers of
capacity to utilize fatty acids in human skeletal muscle: relation to insulin
resistance and obesity and effects of weight loss. The FASEB Journal 13:
2051–2060.
114. Belmadani S, Palen DI, Gonzalez-Villalobos RA, Boulares HA, Matrougui K
(2008) Elevated epidermal growth factor receptor phosphorylation induces
resistance artery dysfunction in diabetic db/db mice. Diabetes 57: 1629–1637.
115. Benter IF, Yousif MH, Griffiths SM, Benboubetra M, Akhtar S (2005)
Epidermal growth factor receptor tyrosine kinase-mediated signalling contrib-
utes to diabetes-induced vascular dysfunction in the mesenteric bed.
Br J Pharmacol 145: 829–836.
116. Pozuelo Rubio M, Geraghty KM, Wong BH, Wood NT, Campbell DG, et al.
(2004) 14-3-3-affinity purification of over 200 human phosphoproteins reveals
new links to regulation of cellular metabolism, proliferation and trafficking.
Biochem J 379: 395–408.
117. Ogihara T, Isobe T, Ichimura T, Taoka M, Funaki M, et al. (1997) 14-3-3
protein binds to insulin receptor substrate-1, one of the binding sites of which is
in the phosphotyrosine binding domain. J Biol Chem 272: 25267–25274.
118. Gual P, Le Marchand-Brustel Y, Tanti JF (2005) Positive and negative
regulation of insulin signalling through IRS-1 phosphorylation. Biochimie 87:
99–109.
119. Cheyssac C, Lecoeur C, Dechaume A, Bibi A, Charpentier G, et al. (2006)
Analysis of common PTPN1 gene variants in type 2 diabetes, obesity and
associated phenotypes in the French population. BMC Med Genet 7: 44.
120. Zhang S, Zhang ZY (2007) PTP1B as a drug target: recent developments in
PTP1B inhibitor discovery. Drug Discov Today 12: 373–381.
121. Caselli A, Mazzinghi B, Camici G, Manao G, Ramponi G (2002) Some protein
tyrosine phosphatases target in part to lipid rafts and interact with caveolin-1.
Biochem Biophys Res Commun 296: 692–697.
122. Cohen AW, Combs TP, Scherer PE, Lisanti MP (2003) Role of caveolin and
caveolae in insulin signalling and diabetes. Am J Physiol Endocrinol Metab
285: E1151–1160.
123. Wright E Jr, Scism-Bacon JL, Glass LC (2006) Oxidative stress in type 2
diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 60:
308–314.
124. Yu T, Fox RJ, Burwell LS, Yoon Y (2005) Regulation of mitochondrial fission
and apoptosis by the mitochondrial outer membrane protein hFis1. J Cell Sci
118: 4141–4151.
125. Lee S, Jeong SY, Lim WC, Kim S, Park YY, et al. (2007) Mitochondrial fission
and fusion mediators, hFis1 and OPA1, modulate cellular senescence. J Biol
Chem 282: 22977–22983.
126. Patel S, Doble BW, MacAulay K, Sinclair EM, Drucker DJ, et al. (2008)
Tissue-specific role of glycogen synthase kinase 3beta in glucose homeostasis
and insulin action. Mol Cell Biol 28: 6314–6328.
127. Vincent PA, Xiao K, Buckley KM, Kowalczyk AP (2004) VE-cadherin:
adhesion at arm’s length. Am J Physiol Cell Physiol 286: C987–997.
Network Biology
PLoS ONE | www.plosone.org 17 December 2009 | Volume 4 | Issue 12 | e8100